

## Statement of Work (SOW) SP 24-024

### SP 24-024 – *In vitro* mRNA+TBP studies

This SOW is subject to the terms as defined in the contract between Allero Therapeutics and VRI “COLLABORATION FRAMEWORK AGREEMENT” (2023).

#### Scope:

[REDACTED]

SOW\_SP 24-024 is based on a study protocol mutually agreed upon by VRI and Allero, and is attached as Annex I as integral part to this SOW.

Sponsor: Allero Therapeutics BV, Marconistraat 16, 3029AK Rotterdam, The Netherlands

Contacts: - [REDACTED]

Tel: [REDACTED]

E-mail: [REDACTED]

- [REDACTED]

Tel: [REDACTED]

E-mail: [REDACTED]

Study site: Veterinary Research Institute, Department of Pharmacology and Toxicology, Hudcova 296/70, Brno 621 00, Czech Republic. VAT: CZ00027162

Contacts: - [REDACTED]

Tel: [REDACTED]

E-mail: [REDACTED]

- [REDACTED]

Tel: [REDACTED]

E-mail: [REDACTED]

OBJECTIVE:

[REDACTED]

[REDACTED]

[REDACTED]

BUDGET SPECIFICATION:

[REDACTED]

[REDACTED]

[REDACTED]

TOTAL COSTS: 15,200 EUR

[REDACTED]

PAYMENT SCHEDULE:

The total amount of 15,200 EUR shall be paid by Allero Therapeutics to VRI upon acceptance and approval of the final report.

TIMELINES:

- Effective date: Upon signature and disclosure in the Register of Contracts.
- Completion of experimental work: no later than August 15, 2025.
- Submission of the final report: no later than August 31, 2025.

CONDITIONS OF VALIDITY:

According to Czech legislation, Act No. 340/2015 Coll., this SOW becomes valid upon signature by the Parties and effective upon disclosure in the Register of Contracts.

STATEMENT OF WORK 24-024



CONFIDENTIAL

Allero Therapeutics and Veterinary Research Institute agree with the SOW including budget specification.

Date:

Allero Therapeutics

[Redacted Signature]

-----

Veterinary Research Institute

[Redacted Signature]

-----

*Appendix 1. to Statement of Work (SOW) SP 24-024*

*SP 24-024 – In vitro mRNA+TBP studies*

Scope:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Introduction:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

[illegible]

[illegible]

██████████

\_\_\_\_\_

[illegible]

\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Government	Percentage
Current government	85%
Previous government	10%
No government	5%

## 2. STUDY DESIGN AND PROCEDURES

### 3. STATISTICAL ANALYSIS

#### STATEMENT OF WORK 24-024



[REDACTED]

#### 4. ETHICAL ASPECTS

[REDACTED]